Modality
Gene Editing
MOA
SOS1i
Target
VEGF
Pathway
Lipid Met
Heart Failure
Development Pipeline
Preclinical
Jul 2017
→ May 2025
PreclinicalCurrent
NCT08780111
2,221 pts·Heart Failure
2017-07→2025-05·Not yet recruiting
NCT03005777
839 pts·Heart Failure
2022-12→TBD·Not yet recruiting
3,060 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-05-2110mo agoInterim· Heart Failure
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3
Preclinical
Not yet…
Preclinical
Not yet…
Catalysts
Interim
2025-05-21 · 10mo ago
Heart Failure
Not yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08780111 | Preclinical | Heart Failure | Not yet recr... | 2221 | CfB |
| NCT03005777 | Preclinical | Heart Failure | Not yet recr... | 839 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| REG-647 | Regeneron | Preclinical | SMN2 | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| Cevisacituzumab | Alnylam | Preclinical | MALT1 |